---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002460"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T18:56:16.350985+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corvus Pharmaceuticals regains Nasdaq minimum bid price compliance

## Summary
- Received Nasdaq deficiency notice on Oct 25, 2022 for bid price below $1.00.
- Compliance period was 180 days, expiring April 24, 2023.
- On April 21, 2023, Nasdaq confirmed compliance after 10 consecutive business days of closing bid price at or above $1.00 from April 6-20.
- Matter is now closed; no further action needed on listing requirement.

## SEC filing metadata
- accession: 0001171843-23-002460
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184323002460/0001171843-23-002460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184323002460/f8k_042423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002460
- JSON: https://secwatch.observer/filing/0001171843-23-002460.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.